Paper Details

  1. Home
  2. Paper Details

Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.

Author: DescampsDominique, HuangLi-Min, LinLan, LinTzou-Yien, PanzerFalko, SchwarzTino F, SuryakiranPemmaraju V, ValenciaAlejandra, WittermannChristoph

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The HPV-16/18 AS04-adjuvanted vaccine induced high anti-HPV-16 and -18 antibody levels up to 6 years postvaccination, predicted to remain above levels induced by natural infection for at least 20 years. The vaccine's safety profile was clinically acceptable.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine were evaluated up to 6 years postvaccination (month 72) in preteen/adolescent girls. METHODS: Participants, who had received 3 HPV-16/18 AS04-adjuvanted vaccine doses at 10-14 years of age in an initial controlled, obser...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/INF.0000000000000460

データ提供：米国国立医学図書館（NLM）

Long-Term Immunogenicity and Safety of HPV Vaccine: A Beacon of Hope in the Desert of Cervical Cancer

Cervical cancer, a significant health concern, has been targeted by vaccination efforts. This study examines the long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls. The researchers conducted a long-term follow-up study to assess the persistence of vaccine-induced antibodies and monitor safety outcomes up to 6 years after vaccination.

Long-Term Immunogenicity: A Durable Oasis in the Desert of Cervical Cancer

This study provides reassuring evidence of the long-term effectiveness of the HPV-16/18 AS04-adjuvanted vaccine. The researchers found that vaccine-induced antibodies remained high for up to 6 years, suggesting durable protection against HPV infection and cervical cancer.

Navigating the Desert of Cervical Cancer with Confidence

This study emphasizes the importance of vaccination in preventing cervical cancer. It provides further evidence of the safety and efficacy of the HPV-16/18 AS04-adjuvanted vaccine, encouraging continued efforts to promote widespread vaccination against this potentially life-threatening disease.

Dr.Camel's Conclusion

This study offers a beacon of hope in the desert of cervical cancer. The long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine provide valuable reassurance, encouraging continued efforts to combat this disease through widespread vaccination.

Date :
  1. Date Completed 2015-06-26
  2. Date Revised 2014-11-12
Further Info :

Pubmed ID

24978856

DOI: Digital Object Identifier

10.1097/INF.0000000000000460

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.